Antidyskinetic effect of A2Aand 5HT1A/1Breceptor ligands in two animal models of Parkinson's disease

Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson’s disease?

(2015) Erwan Bezard et al.   BRAIN

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study

(2015) Per Svenningsson et al.   BRAIN

Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued

(2014) Annalisa Pinna   CNS DRUGS

l-DOPA disrupts adenosine A2A–cannabinoid CB1–dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies

(2014) Annalisa Pinna et al.   EXPERIMENTAL NEUROLOGY

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients

(2014) Marios Politis et al.   JOURNAL OF CLINICAL INVESTIGATION

Effects of l-tryptophan on l-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease

(2014) Wai Kin D. Ko et al.   NEUROSCIENCE LETTERS

Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations

(2014) Manolo Carta et al.   Frontiers in Neurology

Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia

(2013) Erwan Bezard et al.   MOVEMENT DISORDERS

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia

(2013) Erwan Bézard et al.   NEUROSCIENCE RESEARCH

PSD-95 expression controls l-DOPA dyskinesia through dopamine D1 receptor trafficking

(2012) Gregory Porras et al.   JOURNAL OF CLINICAL INVESTIGATION

A critique of available scales and presentation of the non-human primate dyskinesia rating scale

(2012) Susan H. Fox et al.   MOVEMENT DISORDERS

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

(2011) Robert A Hauser et al.   LANCET NEUROLOGY

Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia

(2011) M. Carta et al.   NEUROSCIENCE

Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders

(2010) Robert A. Hodgson et al.   EXPERIMENTAL NEUROLOGY

A long-term study of istradefylline in subjects with fluctuating Parkinson's disease

(2010) Stewart Factor et al.   PARKINSONISM & RELATED DISORDERS

Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia

(2010) S. Fasano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lentiviral Overexpression of GRK6 Alleviates L-Dopa-Induced Dyskinesia in Experimental Parkinson's Disease

(2010) M. R. Ahmed et al.   Science Translational Medicine

Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson's Patients with Neural Transplants

(2010) M. Politis et al.   Science Translational Medicine

A new ethyladenine antagonist of adenosine A2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug

(2009) Annalisa Pinna et al.   NEUROPHARMACOLOGY

Rodent models of treatment-induced motor complications in Parkinson's disease

(2009) M. Angela Cenci et al.   PARKINSONISM & RELATED DISORDERS

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

(2008) A. Munoz et al.   BRAIN